Latest Blogs

Guest Commentary
May 20, 2019
Moving Towards Health Equity: Join the Conversation With #ASCOHealthEquity
Health Equity Committee chair Dr. William D. Tap highlights the recent work and forward momentum of ASCO's efforts to achieve health care equity for all through improved access to and quality of care.
Clifford A. Hudis, MD, FACP, FASCO
May 20, 2019
The Impact of Utilization Management on Patients and Practices: A Conversation with Dr. Jeffery Ward
Dr. Ward and I discuss the policies that public and private insurers use to control the use of anticancer drug therapies, such as prior authorization requirements, restrictive formularies, step therapy, or fail first requirements, and specialty specific tiers.
Miriam Knoll, MD
May 17, 2019
My Best Tips for Preparing for ASCO’s Annual Meeting
To help you get the most out of #ASCO19, I'm sharing a vlog on networking (it's not as scary as you think!) and strategies for organizing your schedule and maximizing your face time with the people you want to meet.
Don S. Dizon, MD, FACP, FASCO
May 16, 2019
Letting Go, Not Giving Up: Accepting the Reality of a Cancer Diagnosis
My patient had struggled emotionally throughout the course of her cancer treatment, until the day I walked into the room and noticed a profound change.
Subscribe to this column

Edward Paul Balaban, DO, FACP, FASCO

Edward P. Balaban, DO, FACP, FASCO, is the Medical Director for the Cancer Care Partnership with Penn State University Cancer Institute and Professor of Medicine Penn State Hershey Cancer Institute. He currently serves as a Practice Guideline Implementation Network (PGIN) representative for Weight-Based Dosing Chemotherapy for Cancer Patients and Gastrointestinal Guideline Advisory Groups. Dr. Balaban is also Past President of the Pennsylvania Society of Oncology and Hematology and the delegate representing ASCO at the AMA-House of Delegates.

Nov 19, 2018
AMA House of Delegates: This Timeline Grows Short
At a recent meeting, the ASCO delegation to the AMA House of Delegates presented concerns focused on the Competitive Acquisition Program (CAP), among a variety of other issues.
Jun 22, 2018
So Busy and So Worthwhile: ASCO and the AMA House of Delegates
At the most recent meeting, ASCO's delegation to the AMA House of Delegates were involved in resolutions related to Pharmacy Benefit Managers, opioids, billing for survivorship care plans, alcohol as a modifiable risk for cancer, and more.
Nov 20, 2017
Aloha from the ASCO AMA House of Delegates
The ASCO delegation was very busy at the American Medical Association House of Delegates recent interim meeting.
Jun 29, 2017
AMA House of Delegates: These are Impactful Times
The most recent meeting of the AMA House of Delegates was a particularly important one for oncologists and cancer-related issues.
Nov 28, 2016
Become Engaged, Stay Engaged: More Important Than Ever
We (the ASCO delegation) have just returned from the interim American Medical Association (AMA) House of Delegates meeting in Orlando. ASCO proposed a resolution focused on the restrictive opioid policies being adopted by many states. Many of the state legislations include language restricting...
Jun 22, 2016
So Much Done, So Much More to Do: AMA House of Delegates Report
ASCO composed and successfully brought to the AMA-HOD several resolutions representing some of our most pressing concerns and/or initiatives, including regulations on handling hazardous materials, transparency on clinical pathways, reimbursement models, and Part B drug payments.

Pages